New Blood Test for Early Detection of Ovarian Cancer

Researchers have created a straightforward blood test aimed at detecting ovarian cancer in its early stages, which could lead to significantly better outcomes for women facing this illness.

Each year, over 300,000 women, predominantly those over 50, receive a diagnosis of ovarian cancer globally, as reported by the World Cancer Research Fund. The disease often goes undiagnosed until later stages, making treatment considerably more challenging.

This new test, developed by teams from the UK and the US, identifies two types of blood markers in individuals exhibiting symptoms like pelvic discomfort and abdominal bloating. By employing machine learning, it can uncover patterns that might elude human analysis.

Presently, a combination of imaging techniques and biopsies—such as ultrasound, CT scans, and various surgical methods—are usually utilized for diagnosis. Early signs of the disease, including bloating, rapid satiety, or frequent urination, are often subtle and not immediately linked to cancer.

The blood test focuses on substances released into the bloodstream by ovarian cancer cells, even in initial stages of the disease.

These cancer cells emit fragments carrying small, fat-like molecules known as lipids, along with specific proteins. This combination serves as a unique biological identifier for ovarian cancer, according to AOA Dx, the test’s developer.

Additionally, the test employs an algorithm optimized on thousands of patient samples to identify subtle variations within lipids and proteins that could indicate ovarian cancer.

Alex Fisher, chief operating officer and co-founder of AOA Dx, stated that this test can detect the disease at earlier stages with greater accuracy compared to existing diagnostic tools.

Dr. Abigail McElhinny, chief science officer at AOA Dx, commented on the method: “Using machine learning to integrate multiple biomarker types has led us to create a diagnostic tool capable of identifying ovarian cancer across various molecular complexities, including its subtypes and stages.”

She further noted, “This platform presents a significant chance to enhance early detection, potentially leading to improved patient outcomes and reduced healthcare costs.”

A study involving the universities of Manchester and Colorado, published in the American Association of Cancer Research journal, examined 832 samples using the AOA Dx method.

In samples from the University of Colorado, the test accurately identified ovarian cancer in 93% of cases across all disease stages, and 91% in early stages. Meanwhile, samples from the University of Manchester yielded a 92% accuracy rate for all stages and 88% for early detection.

Emma Crosbie, a professor at the University of Manchester and a consultant in gynecological oncology, remarked that the AOA Dx platform has the potential to greatly enhance patient care and outcomes for those diagnosed with ovarian cancer.

She expressed enthusiasm for furthering this vital research through more prospective trials to deepen knowledge about how this test could be integrated within existing healthcare infrastructures.